Portal de investigación
ESTUDIO DE FASE 1/2, MULTICÉNTRICO, ABIERTO PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE CC-92480 EN MONOTERAPIA Y EN COMBINACIÓN CON DEXAMETASONA EN SUJETOS CON MIELOMA MÚLTIPLE EN RECAÍDA Y REFRACTARIO.
Datos básicos
- Código:
- CC-92480-MM-001
- Protocolo:
- CC-92480-MM-001
- EUDRACT:
- 2017-001236-19
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2020
- Año de finalización:
- 2021
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[[en]]Peripheral access ultrafiltration in adults with complex congenital heart disease and refractory congestion.
Guerrero Cervera B; (...); Almenar Bonet L
Article. 10.1016/j.rec.2024.08.015. 2024
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
Rios-Tamayo, Rafael; (...); Mateos, Maria Victoria
Article. 10.1080/16078454.2023.2178997. 2023
-
-
-
PlumX Metrics
- Citations
- Policy Citations: 1
- Citation Indexes: 1
- Captures
- Readers: 12
- Mentions
- News Mentions: 1
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Vallejo C; (...); Codesido ML
Article. 10.1007/s00277-023-05602-x. 2024
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco
Article. 10.1080/10428194.2021.1971216. 2021
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.1016/j.transci.2021.103342. 2022
ADAMTS13 RECOVERY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER CAPLACIZUMAB THERAPY. THE SPANISH REGISTRY.
Mingot-Castellano, Maria Eva; (...); Pascual Izquierdo, Cristina
Article. 10.1182/blood.2023022725. 2024
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators
Article. 10.1080/21645515.2021.1953346. 2021
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 24
- Policy Citations: 3
- Captures
- Readers: 59
- Mentions
- News Mentions: 1
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar, Noffar; (...); Costa, Luciano
Meeting Abstract. 10.1182/blood-2023-180013. 2023
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.; (...); Costa, Luciano J.
Meeting Abstract. 10.1182/blood-2022-159009. 2022
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8010. 2021
Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-184837. 2023
ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD RESPONSE AND RESIDUAL DISEASE CRITERIA
Puig, N.; (...); Mateos, M., V
Meeting Abstract. 2021
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study.
de la Asunción CS; (...); Navarro D
Article. 10.1002/jmv.28933. 2023
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Puig, Noemi; (...); Mateis, Maria-Victoria
Meeting Abstract. 10.1182/blood-2021-151557. 2021
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease.
Martí-Aguado D; (...); Martí-Bonmatí L
Article. 10.1148/radiol.2021211027. 2022
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
Pascual-Izquierdo C; (...); Mingot-Castellano ME
Article. 10.1002/ajh.27498. 2024
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-162584. 2022
Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. https://doi.org/10.1182/blood-2022-162584. 2024
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
De la Rubia, Javier; (...); Alegre, Adrian
Meeting Abstract. 10.1182/blood-2022-158538. 2022
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia, Javier; (...); Alegre, Adrian
Article. 10.3390/cancers15112964. 2023
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Gomez-Segui, I, Izquierdo, CP, Comos, JD
Review. 10.1080/17474086.2021.1956898. 2021
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
Lahuerta Palacios, Juan Jose; (...); Blade, Joan
Meeting Abstract. 2022
CA125: a new biomarker in patients with Fontan circulation (vol 76, pg 112, 2023)
Fuentes, Francisco Buendia; (...); Soriano, Joaquin Rueda
Correction. 10.1016/j.rec.2023.03.018. 2023
CA125: a new biomarker in patients with Fontan circulation.
Fuentes, Francisco Buendia; (...); Soriano, Joaquin Rueda
Article. 10.1016/j.rec.2022.05.029. 2022
Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)
Coppo, Paul; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2023-179316. 2023
Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry
Gomez Segui, Ines; (...); De La Rubia, Javier
Meeting Abstract. 10.1182/blood-2023-180970. 2023
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Garces, Juan-Jose; (...); Paiva, Bruno
Article. 10.1200/JCO.21.01365. 2022
Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood-2023-177571. 2023
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Muntañola A; (...); Bosch F
Letter. 10.1186/s40164-020-00195-x. 2020
Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies
Askari, Elham; (...); Garcia-Sanz, Ramon
Meeting Abstract. 10.1182/blood-2023-189581. 2023
Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-165441. 2022
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
COMPARATIVE STUDY OF THE CHARACTERISTICS OF THE DIAGNOSIS AND RESPONSE TO TREATMENT IN PATIENTS AGED=60 YEARS VS. <60 YEARS WITH ACQUIRED PURPLE THROMBOTIC THROMBOCYTOPENIC. RESULTS OF THE SPANISH REGISTRATION OF PTT (REPTT)
Aracil Eva, Frances; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
CONCURRENT MUTATIONS IN ZRSR2 AND TET2 CAUSE SMD-COMPATIBLE ANOMALIES IN A MOUSE MODEL
Cristian, Garcia-Ruiz; (...); Alejandra, Sanjuan-Pla
Meeting Abstract. 2021
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-148423. 2021
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Mateos, Maria-Victoria; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-159606. 2022
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F
Article. 10.1200/JCO.23.02771. 2024
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1111/bjh.17732. 2021
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose
Article. 10.1016/j.gastrohep.2023.05.010. 2023
CHRONOLOGICAL AGE AS A PROGNOSTIC FACTOR IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS NOT CANDIDATED FOR TRANSPLANTATION
Martinez Elena, Meseguer; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
Garcia Ruiz, Raquel; (...); de la Rubia, Javier
Meeting Abstract. 2021
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Moreau, Philippe; (...); Goldschmidt, Hartmut
Letter. 10.1038/s41408-023-00805-x. 2023
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)
Lozano, Maria L.; (...); Vicente, Vicente
Article. 10.1038/s41598-021-95732-x. 2021
Decreased clinical performance in TGA-ASO patients after RVOT interventions; a multicenter European collaboration.
Engele LJ; (...); Bouma BJ
Article. 10.1016/j.ijcard.2024.132027. 2024
DEEP INTRONIC MUTATIONS IN THE RUNX1 AND FLT3 GENES PRODUCE OPENING SPLICING IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Mireia, Boluda-Navarro; (...); Jose, Cervera
Meeting Abstract. 2021
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
Burgos, Leire; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2021-150092. 2021
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire; (...); Paiva, Bruno
Article. 10.1200/JCO.22.01916. 2023
Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Joseph, Mikhael; (...); Meletios, A. Dimopoulos
Article. 2022
Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 2022
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
Mansilla-Polo M; (...); Botella-Estrada R
Letter. 10.1111/ddg.15502. 2024
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3390/ijms24054440. 2023
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.1111/liv.15766. 2024
Diagnosis and treatment of patients with ANOCA. Consensus document of the SEC-Clinical Cardiology Association/SEC-Interventional Cardiology Association/SEC-Ischemic Heart Disease and Acute Cardiac Care Association/SEC-Cardiovascular Imaging Association
Escobar, Carlos; (...); Tejedor, Ana Viana
Article. https://doi.org/10.24875/RECICE.M23000420. 2024
Diagnosis of non-Hodgkin's lymphoma due to a tiny polyp in the cecum.
Argumánez Tello V; (...); Bustamante-Balén M
Article. 10.17235/reed.2023.9543/2023. 2023
Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease.
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.3390/biom11121808. 2021
Does hyaluronidase injected in periocular area change skin ultrastructure?: Standardized in vitro analysis
Aguilar-González M; (...); Pérez-López M
Article. 10.1111/jocd.15014. 2022
Editorial: Infectious diseases and hematology: diagnosis and management
Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo
Editorial Material. 10.3389/fmed.2024.1385874. 2024
Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)
Eva Mingot, Maria; (...); Del Rio Garma, Julio
Meeting Abstract. 10.1182/blood-2023-182876. 2023
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Ferra, Christelle; (...); Baltasar, Patricia
Meeting Abstract. 10.1182/blood-2022-162186. 2022
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study
Baltasar, Patricia; (...); Ferra, Christelle
Meeting Abstract. 10.1182/blood-2021-147685. 2021
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 162
- Policy Citations: 2
- Captures
- Readers: 176
- Mentions
- News Mentions: 3
- References: 1
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY
Risitano, Antonio Maria; (...); de Latour, Regis Peffault
Meeting Abstract. 2024
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish; (...); Prince, H. Miles
Meeting Abstract. 10.1182/blood-2023-179818. 2023
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria
Article. 10.1182/blood.2024024250. 2024
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial
Medina, Alejandro; (...); Garcia-Sanz, Ramon
Meeting Abstract. 2023
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 10
- Policy Citations: 2
- Captures
- Readers: 26
- Mentions
- News Mentions: 1
GERMINAL PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR DISORDERS AND CLINICAL HISTORY
Marta, Santiago; (...); Jose, Cervera
Meeting Abstract. 2021
GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
Santiago, M.; (...); Cervera-Zamora, J.
Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina
Meeting Abstract. 10.1182/blood-2023-180743. 2023
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Rodriguez-Otero, Paula; (...); Gutierrez, Norma
Meeting Abstract. 2023
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.
Article. 10.1002/hem3.70031. 2024
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, Felipe, Montes Gaisan, Carmen, de la Rubia Comos, Javier
Review. 10.3390/cancers15010155. 2023
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Abrisqueta, Pau; (...); Bosch, Francesc
Article. 10.1016/j.eclinm.2024.102642. 2024
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.
Vallejo, Carlos; (...); Peman, Javier
Article. 10.3390/jof9060628. 2023
Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 2022
Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163058. 2022
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT).
Gomez-Segui, I; (...); de la Rubia Comos, J
Article. 10.1111/bjh.19109. 2023
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
de la Asuncion Carlos, Solano; (...); Navarro, David
Letter. 10.1111/bjh.18655. 2023
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S; (...); Hernández MT
Article. 10.1007/s00277-024-06031-0. 2024
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Immunotherapy in multiple myeloma.
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J
Article. 10.1016/j.medcli.2023.11.019. 2024
Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients
Serna, Angel; (...); Abrisqueta, Pau
Meeting Abstract. 10.1182/blood-2024-207871. 2024
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martinez, Carmen; (...); Garcia-Sanz, Ramon
Article. 10.1007/s00277-022-05011-6. 2022
Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies
Moreno, David; (...); Rosinol, Laura
Meeting Abstract. 2021
Impact on Survival of Heart and Heart-Lung Transplantation in Patients With Cyanotic and Noncyanotic Congenital Heart Diseases.
Donoso-Trenado, Victor; (...); Almenar-bonet, Luis
Article. 10.1016/j.transproceed.2024.12.005. 2024
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema
Vallejo, C; (...); Jarque, I
Meeting Abstract. 2020
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura
Pascual-Izquierdo, C; (...); Salinas, R
Article. 10.1002/jca.21894. 2021
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8034. 2021
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos, Meletios A.; (...); Hajek, Roman
Article. 10.1002/ajh.26602. 2022
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-182964. 2023
ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
Ghobrial, Irene; (...); Mateos, Maria-Victoria
Meeting Abstract. 2021
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
Ki-67 immunoexpression and radiological assessment of necrosis improves accuracy of conventional and modified core biopsy systems in predicting the final grade assigned to adult-soft tissue sarcomas. An international collaborative study
Machado, I; (...); Llombart-Bosch, A
Article. 10.1016/j.prp.2021.153562. 2021
Left atrial strain in adults after the arterial switch operation for transposition of the great arteries.
Buendia-Fuentes, Francisco; (...); Rueda, Joaquin
Article. 10.1111/echo.15750. 2024
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosinol, Laura; (...); Blade, Joan
Article. 10.1182/blood.2022019531. 2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martin Garcia-Sancho, A.; (...); Caballero, D.
Article. 10.1111/bjh.18989. 2023
LONG TERM OUTCOMES OF ADULTS WITH SINGLE VENTRICLE PHYSIOLOGY NOT UNDERGOING FONTAN REPAIR: A MULTICENTRE EXPERIENCE.
Buendia-Fuentes, Francisco; (...); Rueda-Soriano, Joaquin
Article. 10.1016/j.cjca.2021.06.001. 2021
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig, Noemi; (...); Mateos, Maria-Victoria
Article. 10.1182/bloodadvances.2021006762. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Richardson PG; (...); Bahlis NJ
Article. 10.1056/NEJMoa2303194. 2023
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
MOLECULAR APPROACH TO CHRONIC LYMPHOPROLIFERATIVE SYNDROMES IN THE DAILY CLINICAL PRACTICE OF A SINGLE CENTER
Mariam, Ibanez; (...); Irene, Luna
Meeting Abstract. 2021
MOLECULAR CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS BY USING A SINGLE ENRICHMENT PANEL IDENTIFYING SNVS, INDELS, CNVS AND TRANSLOCATIONS
Juan Manuel, Rosa-Rosa; (...); Joaquin, Martinez-Lopez
Meeting Abstract. 2021
MRI-PDFF captures the whole spectrum of lipid composition beyond traditional histological evaluation of macrosteatosis
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2023
Multi- Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target
Medina, Daniel; (...); Crespo, Marta
Meeting Abstract. 10.1182/blood-2023-185683. 2023
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa, Juan Manuel; (...); Martinez-Lopez, Joaquin
Article. 10.3390/cancers14205169. 2022
Non-traumatic spontaneous abdominal haemorrhage
Ballesta, M.; (...); Lerga, P. Estelles
Article. 10.1016/j.rx.2022.11.003. 2023
Non-traumatic spontaneous abdominal haemorrhage.
Ballesta M; (...); Estellés Lerga P
Article. 10.1016/j.rxeng.2022.11.004. 2023
Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients
Serna, Angel; (...); Abrisqueta Costa, Pau
Meeting Abstract. 10.1182/blood-2023-186019. 2023
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial
Cabrero, M; (...); Caballero, D
Meeting Abstract. 2020
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group
Munoz, Maria Carmen Martinez; (...); Balari, Anna Sureda
Meeting Abstract. 10.1182/blood-2024-205007. 2024
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)
Ghobrial, Irene M.; (...); Mateos, Maria-Victoria
Correction. 10.1016/j.clml.2022.03.011. 2022
Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease.
Marti-Aguado D; (...); Marti-Bonmati L
Article. 10.3389/fendo.2023.1213441. 2023
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory
Gaya, Anna; (...); Vallejo, Carlos
Meeting Abstract. 10.1182/blood-2023-185939. 2023
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando
Article. 10.1016/j.blre.2023.101112. 2023
Primary Pulmonary Artery Sarcoma: A Rare Tumor Diagnosed by EBUS Guided Mediastinal Cryobiopsy.
Cuenca Peris S, Bauza M, Briones Gómez A
Article. 10.1016/j.arbres.2024.04.014. 2024
Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo
Huguet, Maria; (...); Navarro, Jose-Tomas
Meeting Abstract. 10.1182/blood-2023-189756. 2023
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
-
-
-
PlumX Metrics
- Citations
- Policy Citations: 1
- Citation Indexes: 2
- Captures
- Readers: 16
- Mentions
- News Mentions: 1
PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2021
Pulmonary arterial hypertension associated with pretricuspid shunts: risk profile and survival.
Calvo-Asensio, Maria; (...); Rueda Soriano, Joaquin
Article. 10.1016/j.rec.2024.04.016. 2024
Púrpura trombocitopénica trombótica inmune: sospecha y manejo básico en los servicios de urgencias. Revisión y consenso de un grupo de expertos de las sociedades científicas SEHH y SEMES.
Pascual-Izquierdo, Cristina; (...); de la Rubia Comos, Javier
Article. 10.55633/s3me/E099.2023. 2023
QUANTIFICATION OF CIRCULATING TUMOR CELLS IS THE MOST RELEVANT PROGNOSTIC FACTOR AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA, WHO ARE TRANSPLANT CANDIDATES, Abstracts
Juan-Jose, Garces; (...); Bruno, Paiva
Meeting Abstract. 2021
Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project
Costa, Luciano; (...); Wong, Sandy
Meeting Abstract. 2023
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.
Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro
Article. 10.1080/09537104.2024.2336104. 2024
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, Pau; (...); Villanueva, Miguel
Article. 10.1016/j.clml.2021.07.022. 2021
Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.
Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio
Article. 10.1182/bloodadvances.2022008028. 2022
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).
Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina
Article. 10.3390/jcm12206422. 2023
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Mingot Castellano, Maria Eva; (...); Grp Espanol Aferesis GEA
Practice Guideline. 10.1016/j.medcli.2021.03.040. 2022
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: update on laboratory tests for the study of monoclonal gammopathies.
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0326. 2023
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0325. 2023
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; (...); Hernández MT
Article. 10.3324/haematol.2023.284154. 2024
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.
García-Vidal C, Vázquez L, Jarque I
Article. 10.1016/j.riam.2021.03.001. 2021
Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)
Garcia-Guinon, Antonio; (...); de la Rubia, Javier
Meeting Abstract. 2021
Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients
de Latour, RP; (...); Risitano, A
Meeting Abstract. 2020
Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.3390/hemato5020009. 2024
SEQUENCING OF THE EXOME IN THE RECALLING OR REFRACTORY AML
Simarro Claudia, Sargas; (...); Eva, Barragan
Meeting Abstract. 2021
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study
Stefania Infante, Maria; (...); Grande, Carlos
Article. 10.1002/cam4.4293. 2021
Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
Martinez-Lopez, Joaquin; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-149192. 2021
Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
Seguí IG; (...); de la Rubia J
Article. 10.1080/17474086.2024.2318347. 2024
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)
Villalba, Ana; (...); De la Rubia, Javier
Meeting Abstract. 2022
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N; (...); Mateos MV
Article. 10.3324/haematol.2024.285742. 2024
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel
Meeting Abstract. 10.1182/blood-2023-179452. 2023
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; (...); Garcia-Sanz R
Article. 10.1038/s41408-024-01053-3. 2024
The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
Strebel, Johanna A. Kremer Hovinga; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2022-156306. 2022
The sentinel node with technetium-99m for prostate cancer. A safe and, mature new gold standard?
Perez-Ardavin J; (...); Vera-Donoso CD
Article. 10.23736/S1824-4785.22.03416-1. 2022
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
Quinonero, Isabel Rodenas; (...); Ortuno, Francisco Jose
Article. 10.3390/cancers16244189. 2024
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma
Cejalvo, MJ; (...); de la Rubia, J
Article. 10.1007/s00277-021-04529-5. 2021
-
-
PlumX Metrics
- Citations
- Policy Citations: 1
- Citation Indexes: 11
- Captures
- Readers: 29
- Mentions
- News Mentions: 1
Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bua, BR; (...); Garcia-Sancho, AM
Meeting Abstract. 2021
Use of optical genome mapping in the cytogenetic diagnosis of multiple myeloma
de la Rubia, Javier; (...); Such, Esperanza
Meeting Abstract. 2023
VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS
Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora
Meeting Abstract. 2021
Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jimenez Ubieto, Ana; (...); Lahuerta, Juan-Jose
Article. 10.1182/blood.2021012319. 2021
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
WHOLE GENE SEQUENCING FOR THE IDENTIFICATION OF SPLICING MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Mireya, Morote-Faubel; (...); Jose, Cervera
Meeting Abstract. 2021